Literature DB >> 11529867

A prospective analysis of the pattern of immune reconstitution in a paediatric cohort following transplantation of positively selected human leucocyte antigen-disparate haematopoietic stem cells from parental donors.

M Eyrich1, P Lang, S Lal, P Bader, R Handgretinger, T Klingebiel, D Niethammer, P G Schlegel.   

Abstract

Transplantation of haematopoietic stem cells from human leucocyte antigen (HLA)-disparate parental donors presents a promising new approach for the treatment of patients lacking a HLA-matched donor. Success against major obstacles such as graft-versus-host disease (GvHD) and graft rejection has recently been demonstrated, so that immune reconstitution is one of the prime factors that determines the long-term prognosis following transplantation. Twenty children transplanted with megadoses of highly purified CD34(+) haematopoietic stem cells after rigorous T-cell depletion were prospectively monitored for their immune reconstitution during the first post-transplant year. Natural killer (NK) cells showed a marked increase on d +30. T and B cells began to reconstitute on d +72 and +68 respectively. During extended follow-up, their numbers and proliferative capacity upon mitogen stimulation continually increased. Early reconstituting T cells were predominantly of a primed, activated phenotype with severely skewed T-cell receptor (TCR)-repertoire complexity. Naive T cells emerged 6 months post transplantation, paralleled by an increase in TCR-repertoire diversity. All patients self-maintained sufficient immunoglobulin levels after d +200. This study demonstrates that paediatric recipients of highly purified, haploidentical stem cells are able to reconstitute functioning T-, B- and NK-cell compartments within the first post-transplant year. This, together with the absence of significant GvHD, provides a strong indication for this approach to be considered in children who lack a HLA-matched donor.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11529867     DOI: 10.1046/j.1365-2141.2001.02934.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  15 in total

Review 1.  Evaluation of TCR repertoire diversity in patients after hematopoietic stem cell transplantation.

Authors:  Yangqiu Li; Ling Xu
Journal:  Stem Cell Investig       Date:  2015-09-28

2.  Long-term outcome after haploidentical stem cell transplant and infusion of T cells expressing the inducible caspase 9 safety transgene.

Authors:  Xiaoou Zhou; Antonio Di Stasi; Siok-Keen Tey; Robert A Krance; Caridad Martinez; Kathryn S Leung; April G Durett; Meng-Fen Wu; Hao Liu; Ann M Leen; Barbara Savoldo; Yu-Feng Lin; Bambi J Grilley; Adrian P Gee; David M Spencer; Cliona M Rooney; Helen E Heslop; Malcolm K Brenner; Gianpietro Dotti
Journal:  Blood       Date:  2014-04-21       Impact factor: 22.113

3.  Lymphocyte recovery predicts outcomes in cord blood and T cell-depleted haploidentical stem cell transplantation.

Authors:  Stefan O Ciurea; Victor Mulanovich; Ying Jiang; Roland Bassett; Gabriela Rondon; John McMannis; Marcos de Lima; Elizabeth J Shpall; Richard E Champlin
Journal:  Biol Blood Marrow Transplant       Date:  2010-11-30       Impact factor: 5.742

4.  Prognostic factors and outcomes for pediatric patients receiving an haploidentical relative allogeneic transplant using CD3/CD19-depleted grafts.

Authors:  M A Diaz; A Pérez-Martínez; B Herrero; N Deltoro; I Martinez; M Ramirez; L Abad; J Sevilla; E Merino; J Ruiz; J L Vicario; M Gonzalez-Vicent
Journal:  Bone Marrow Transplant       Date:  2016-04-18       Impact factor: 5.483

5.  Haploidentical allogeneic hematopoietic cell transplantation in adults using CD3/CD19 depletion and reduced intensity conditioning: a phase II study.

Authors:  Birgit Federmann; Martin Bornhauser; Christoph Meisner; Lambros Kordelas; Dietrich W Beelen; Gernot Stuhler; Matthias Stelljes; Rainer Schwerdtfeger; Maximilian Christopeit; Gerhard Behre; Christoph Faul; Wichard Vogel; Michael Schumm; Rupert Handgretinger; Lothar Kanz; Wolfgang A Bethge
Journal:  Haematologica       Date:  2012-04-04       Impact factor: 9.941

6.  The kinetics of immune reconstitution after cord blood transplantation and selected CD34+ stem cell transplantation in children: comparison with bone marrow transplantation.

Authors:  Hiroyasu Inoue; Yukiharu Yasuda; Kinya Hattori; Takashi Shimizu; Masae Matsumoto; Miharu Yabe; Hiromasa Yabe; Fumiko Tsuchida; Yumiko Tanaka; Gaku Hosoi; Masahiro Sako; Shunichi Kato
Journal:  Int J Hematol       Date:  2003-05       Impact factor: 2.490

7.  Outcome of alloanergized haploidentical bone marrow transplantation after ex vivo costimulatory blockade: results of 2 phase 1 studies.

Authors:  Jeff K Davies; John G Gribben; Lisa L Brennan; Dongin Yuk; Lee M Nadler; Eva C Guinan
Journal:  Blood       Date:  2008-07-10       Impact factor: 22.113

8.  Successful rescue of early graft failure in pediatric patients using T-cell-depleted haploidentical hematopoietic SCT.

Authors:  J A Park; K N Koh; E S Choi; S Jang; S W Kwon; C-J Park; J J Seo; H J Im
Journal:  Bone Marrow Transplant       Date:  2013-10-21       Impact factor: 5.483

9.  Adoptive immunotherapy with allodepleted donor T-cells improves immune reconstitution after haploidentical stem cell transplantation.

Authors:  Persis J Amrolia; Giada Muccioli-Casadei; Helen Huls; Stuart Adams; April Durett; Adrian Gee; Eric Yvon; Heidi Weiss; Mark Cobbold; H Bobby Gaspar; Cliona Rooney; Ingrid Kuehnle; Victor Ghetie; John Schindler; Robert Krance; Helen E Heslop; Paul Veys; Ellen Vitetta; Malcolm K Brenner
Journal:  Blood       Date:  2006-06-01       Impact factor: 22.113

10.  Infusion of Alloanergized Donor Lymphocytes after CD34-selected Haploidentical Myeloablative Hematopoietic Stem Cell Transplantation.

Authors:  Jeff K Davies; Lisa L Brennan; John R Wingard; Christopher R Cogle; Neena Kapoor; Ami J Shah; Bimalangshu R Dey; Thomas R Spitzer; Marcos de Lima; Laurence J Cooper; Peter F Thall; Richard E Champlin; Lee M Nadler; Eva C Guinan
Journal:  Clin Cancer Res       Date:  2018-05-16       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.